Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

NCT00233454 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Systemic Mastocytosis, Aggressive (ASM)
Leukemia, Mast Cell
Hematological Non-mast Cell Lineage Disease (AHNMD)

Interventions

DRUG: Midostaurin

Sponsor

Jason Robert Gotlib

Collaborators

[object Object]
[object Object]